Please login to the form below

Not currently logged in
Email:
Password:

PharmaVentures increases its Asia-Pacific presence

Aki von Roy will be based in Auckland, New Zealand

edit-aki2Oxford, UK-headquartered advisory firm PharmaVentures has appointed Aki von Roy as an associate based in Auckland, New Zealand.

He has over 30 years experience in pharma and 16 years in biotech, and has been involved in 18 start up or merger ventures as director or investor.

Von Roy said: “I am delighted to join PharmaVentures, a firm with a proven track record in deal making.”

Formally he was the European president of Bristol-Myers Squibb (BMS), where he was responsible for $2.2bn in sales, more than 7,500 employees and around 40 subsidiaries. In 1997, he retired from BMS to establish RvR Associates, a private investment firm specialising in health and related matters.

Von Roy has also been chairman of private and publicly traded companies such as Genesis R&D, Phylogica, Vital Foods and Phytomedics and currently works as a venture partner at BioPacificVentures and an advisor to Direct Capital.

Fintan Walton, CEO of PharmaVentures, added: “Aki has a unique insight into innovative healthcare in the Asia-Pacific region and he will be a great benefit to both PharmaVentures and its clients.”

26th September 2014

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics